What Researchers Did
Researchers conducted an extensive review of antifungal approaches for treating mucormycosis, a rare and rapidly progressing fungal infection.
What They Found
They found that mucormycosis occurrences increased significantly during the COVID-19 pandemic, associated with high mortality and morbidity. First-line antifungal therapies include Amphotericin B and isavuconazole, while posaconazole and deferasirox are used for salvage therapy in unresponsive patients. Adjunctive therapies such as hyperbaric oxygen and cytokine therapy are also employed alongside first-line treatment.
Canadian Relevance
This review does not specifically address Canadian populations or healthcare contexts.
Study Limitations
As a review article, this study synthesizes existing literature and does not present new primary research or clinical trial data.